Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 14/20 | 0.53 |
| ▸ | LTB4R2 | Q9NPC1 | 5/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.51 |
| ▸ | AGT | P01019 | 2/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12894045 | 1.00 | AGTR1 (0.53) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL8140438 | 0.95 | AGTR1 (0.56) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL2443650 | 0.92 | AGTR1 (0.63) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL29670077 | 0.92 | AGTR1 (0.63) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL1259493 | 0.92 | AGTR1 (0.63) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL4154512 | 0.91 | AGTR1 (0.53) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL1891052 | 0.91 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL2828658 | 0.91 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL28455049 | 0.91 | AGTR1 (0.62) | AGTR1LTB4R2ABCB11GP6AGT | |
| SCHEMBL13773306 | 0.90 | AGTR1 (0.54) | AGTR1LTB4R2ABCB11GP6AGT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111265518-A | Composition containing a mixture of biphenyl derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | disclosed |
| CN-111265518-A | Composition containing a mixture of biphenyl derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | disclosed |
| US-20140316142-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF | ALKEM LABORATORIES LTD. (IN) | 2014-10-23 | — | — | US | disclosed |
| US-20140316142-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF | ALKEM LABORATORIES LTD. (IN) | 2014-10-23 | — | — | US | disclosed |
| WO-2013072924-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF. | ALKEM LABORATORIES LTD. (IN) | 2013-05-23 | — | — | WO | disclosed |
| US-8288561-B2 | Process for preparing valsartan | CIPLA LIMITED (IN) | 2012-10-16 | — | — | US | disclosed |
| US-20110105763-A1 | Process for Preparing Valsartan | CIPLA LIMITED (IN) | 2011-05-05 | — | — | US | disclosed |
| EP-1658281-B1 | A METHOD OF REMOVING THE TRIPHENYLMETHANE PROTECTING GROUP | ZENTIVA KS (CZ) | 2010-09-29 | — | — | EP | disclosed |
| US-20090192318-A1 | Method of preparation of N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-y1) [1,1'-biphenyl]-4-y1]methyl]-L-valine (valsartan) | ZENTIVA, A.S. (CZ) | 2009-07-30 | — | — | US | disclosed |
| EP-1838681-A2 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF AN ANGIOTENSIN II RECEPTOR AND PROCESS FOR THE PREPARATION OF VALSARTAN | Enantia, S.L. (ES) | 2007-10-03 | — | — | EP | disclosed |
| EP-1622882-B1 | A METHOD OF PREPARATION OF N -(1-OXOPENTYL)- N-¬¬ 2-(1TETRAZOL-5-y1) ¬1,1 -BIPHENYL|-4-y1 METHYL| -L-VALINE (VALSARTAN) | ZENTIVA AS (CZ) | 2006-07-12 | — | — | EP | disclosed |
| WO-2006067216-A2 | INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF AN ANGIOTENSIN II RECEPTOR AND PROCESS FOR THE PREPARATION OF VALSARTAN | ENANTIA, S. L. (ES) | 2006-06-29 | — | — | WO | disclosed |
| EP-1622882-A1 | A METHOD OF PREPARATION OF N -(1-OXOPENTYL)- N-[[ 2-(1TETRAZOL-5-y1) [1,1 -BIPHENYL]-4-y1 METHYL] -L-VALINE (VALSARTAN) | ZENTIVA, A.S. (CZ) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004101534-A1 | A METHOD OF PREPARATION OF N-(1-OXOPENTYL)-N-[[2'-(1H-TETRAZOL-5-y1) [1,1'-BIPHENYL] -4-y1]METHYL]-L-VALINE (VALSARTAN) | ZENTIVA, A. S. (CZ) | 2004-11-25 | — | — | WO | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140316142-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II ANTAGONISTS AND INTERMEDIATES THEREOF | AGTR1, AGTR2, AVPR2 | AGTR1 1/4885LTB4R2 747/4885ABCB11 3420/4885 |
| US-20110105763-A1 | Process for Preparing Valsartan | REN, AGT, ACE | AGTR1 7/4885LTB4R2 3287/4885ABCB11 360/4885 |
| US-20090192318-A1 | Method of preparation of N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-y1) [1,1'-biphenyl]-4-y1]methyl]-L-valine (valsartan) | TTR, REN, VARS1 | AGTR1 4/4885LTB4R2 1071/4885ABCB11 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.